The initiative could tackle the first-mover disadvantage some CDMOs believe deters early customers, but leaders at companies ...

HRV Pharma and Haleos Labs have joined forces in a multi-year strategic partnership to fast-track the development and manufacturing of specialized active pharmaceutical ingredients (APIs) for rare ...

Under the agreement, the two companies will jointly undertake co-development of a multi-year pipeline of high-value specialty ...

Market valued at $72.4M in 2024, projected 7.30% CAGR growth driven by pharmaceutical API synthesis, food-grade ...

European regulators are to review Sarepta Therapeutics’ Duchenne muscular dystrophy drug, eteplirsen – a drug that has sparked controversy in the US, where it was approved by the FDA against the ...

Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients. The US ...